acetylcysteine and metformin in induction of ovulatio

Phase 3

• Conditions: Polycystic ovary syndrome.; Polycystic ovary syndrome; E28.2

• Registration Number: IRCT20210310050658N1
• Lead Sponsor: Zanjan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 8 March 2022

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: 50

Inclusion Criteria

aged 20-35 years
infertile with polycystic ovary syndrome candidates for ovulation induction
spouse with normal sperm analysis
with normal hysterosalpingography without tubular pathology

Exclusion Criteria

Endocrine and endocrinological diseases such as thyroid disorders and abnormal prolactin
Patients who used metformin and clomiphene more frequently in the previous cycle to induce ovulation
Clomiphene resistant patients
Pituitary or hypothalamic disorders characterized by low gonadotropin levels
Drug allergy to metformin or N Acetyl Cystein
Simple ovarian cyst
Liver disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of follicles. Timepoint: Four weeks after the intervention. Method of measurement: Transvaginal ultrasound.;Endometrial thickness. Timepoint: Four weeks after the intervention. Method of measurement: Transvaginal ultrasound.;Size of follicles. Timepoint: Four weeks after the intervention. Method of measurement: Transvaginal ultrasound.;Frequency of intrauterine sac. Timepoint: Four weeks after the intervention. Method of measurement: Transvaginal ultrasound.

Secondary Outcome Measures

Name	Time	Method
Positive human chorionic gonadotropin (HCG). Timepoint: Four weeks after the intervention. Method of measurement: ELIZA test.